Status:
TERMINATED
Nitroglycerin in Non-small Cell Lung Cancer
Lead Sponsor:
Maastricht Radiation Oncology
Collaborating Sponsors:
Reliable Cancer Therapies
Anticancer Fund, Belgium
Conditions:
Non Small Cell Lung Cancer (NSCLC)
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Nitroglycerin is a nitric oxide donor which is mainly known as a vasodilating agent used in ischemic heart disease. It has also been shown to increase tumor blood flow in animal and human tumors. The...
Detailed Description
Namely, the failure of many different tumor types to show a lasting response chemotherapy or radiotherapy might be attributable to a lack of oxygen supply (called "hypoxia" from hereon) in a large par...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Non-small cell lung cancer stage IB-IV amenable for radiotherapy with curative intent.
- (Stage IV patients with oligometastic (1-4 metastases) NSCLC are regularly treated radically in the IKNL region).
- Patients not included in the PET-Boost or the Lucanix trial.
- WHO performance status 0-2.
- Willing and able to comply with the study prescriptions.
- 18 years or older.
- Ability to give and having given written informed consent before patient registration.
- No recent (\< 3 months) severe cardiac disease (NYHA class \>1) (congestive heart failure, infarction).
- No radiotherapy in 4 weeks prior to this study.
- No treatment with investigational drugs in 4 weeks prior to or during this study.
- No known allergy to nitroglycerin or nitroglycerin patch.
- No known allergy to iodine based contrast agents
- No use of Levitra, Viagra or Cialis at the time of application of the nitroglycerin patch.
- No conditions necessitating the use of ergot alkaloids, alpha blockers (eg tamsulosine), betablockers or calcium channel blockers on the day of nitroglycerin patch application).
- No other active malignancy.
- No major surgery (excluding diagnostic procedures like eg mediastinoscopy) in previous 4 weeks.
- Adequate renal function: calculated creatinine clearance at least 60ml/min.
Exclusion
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2017
Estimated Enrollment :
47 Patients enrolled
Trial Details
Trial ID
NCT01210378
Start Date
December 1 2011
End Date
March 1 2017
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
MAASTRO clinic
Maastricht, Netherlands, 6229 ET